Shearman & Sterling represented Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Barclays Capital Inc. and Morgan Stanley & Co. LLC as joint book-running managers and representatives of the underwriters in connection with Amgen’s registered $5 billion notes offering, consisting of 1.900 percent senior notes due 2025, 2.200 percent senior notes due 2027, 2.450 percent of senior notes due 2030, 3.150 percent senior notes due 2040 and 3.375 percent senior notes due 2050. 

Amgen is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics based on advances in cellular and molecular biology.

The Team